Literature DB >> 10817879

Neuroendocrine tumors of the uterine cervix. Clinicopathologic study of five patients.

P Collinet1, D Lanvin, D Declerck, A Chevalier-Place, E Leblanc, D Querleu.   

Abstract

Four main clinicopathologic features of neuroendocrine tumors (NETs) of the cervix may be stressed: primary diagnosis at an advanced stage, early nodal metastasis even for low disease, early failure of appropriate local treatment (surgery and/or radiation therapy) and aggressive clinical treatment. Five patients with NET of the uterine cervix (small cell carcinoma type) are reported (one stage I, two stages II, one stage III and one stage IV). One patient was treated by surgery combined with radiation therapy, one by surgery combined with chemotherapy and one by surgery with radiation therapy and chemotherapy. Two patients received radiation therapy alone. Three early stage patients are alive with no evidence of disease 8, 26 and 41 months after diagnosis. The two patients with advanced stage died of disease, 3 and 12 months respectively, after diagnosis. Combination chemotherapy (cisplatin and etoposide) is warranted in disseminated NETs. Neoadjuvant or adjuvant chemotherapy should be combined with radiation therapy and surgery even in early stages.

Entities:  

Mesh:

Year:  2000        PMID: 10817879     DOI: 10.1016/s0301-2115(99)00253-5

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

1.  Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix.

Authors:  W J Tian; M Q Zhang; R H Shui
Journal:  Oncol Lett       Date:  2011-10-12       Impact factor: 2.967

2.  Metastatic Small Cell Carcinoma of the Breast from Cancer of the Uterine Cervix: A Case Report.

Authors:  Beom Seok Kwak
Journal:  Case Rep Oncol       Date:  2018-01-17

3.  Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Authors:  Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek
Journal:  BMC Cancer       Date:  2018-05-04       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.